Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

90.00EUR
11:35am EST
Change (% chg)

€-0.60 (-0.66%)
Prev Close
€90.60
Open
€89.98
Day's High
€90.80
Day's Low
€89.92
Volume
429,784
Avg. Vol
573,652
52-wk High
€100.20
52-wk Low
€74.54

Chart for

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnol... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €12,559.76
Shares Outstanding(Mil.): 129.24
Dividend: 1.25
Yield (%): 1.29

Financials

  MRCG.DE Industry Sector
P/E (TTM): 22.20 29.45 30.88
EPS (TTM): 4.38 -- --
ROI: 7.06 14.34 13.80
ROE: 13.49 15.85 15.29

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

Dec 21 2018

UPDATE 2-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

Dec 21 2018

CORRECTED-UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug, Bavencio, to treat a form of ovarian cancer in previously untreated patients.

Dec 21 2018

Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study

Dec 21 Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

Dec 21 2018

Palantir to offer cancer analytics under JV deal with Germany's Merck

((This NOV 19 story corrects to show Merck is Palantir's exclusive partner within the JV, not for all of Palantir's healthcare activities, paragraph 11))

Nov 20 2018

CORRECTED-UPDATE 1-Palantir to offer cancer analytics under JV deal with Germany's Merck

FRANKFURT, Nov 19 Palantir Technologies Inc will set up a cancer data analytics joint venture with German lab supplies company Merck KGaA, as the U.S. analytics and security firm makes further inroads into health care.

Nov 20 2018

Palantir to offer cancer analytics under JV deal with Germany's Merck

FRANKFURT, Nov 19 Palantir Technologies Inc will set up an exclusive cancer research joint venture with German lab supplies company Merck KGaA, as the U.S. data analytics and security firm makes further inroads into health care.

Nov 19 2018

Merck KGaA third-quarter earnings down on weak Latam currencies

FRANKFURT German drugs and lab supplies maker Merck KGaA saw adjusted core earnings decline and lowered its full-year profit outlook as a decline in Latin American currencies weighed on the value of overseas sales.

Nov 14 2018

Merck KGaA Q3 earnings down on weak Latam currencies

FRANKFURT, Nov 14 German drugs and lab supplies maker Merck KGaA saw adjusted core earnings decline and lowered its full-year profit outlook as a decline in Latin American currencies weighed on the value of overseas sales.

Nov 14 2018

German stocks - Factors to watch on Oct. 22

FRANKFURT/BERLIN, Oct 22 - The following are some of the factors that may move German stocks on Monday:

Oct 22 2018

Earnings vs. Estimates